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ABSTRACT 
 
 
The emergence of new type of drugs known as biologics has led to rapid disease improvements in 
many autoimmune arthritic patients. Nevertheless, most of these biologics are immunomodulators that 
may consequently increase the susceptibility of patients towards infections, such as septic arthritis. 
Septic arthritis is still considered a major public health challenge due to its rapidly progressive disease 
character with poor prognosis regarding joint functions. It is mainly caused by Staphylococcus aureus 
and despite optimal antibiotic treatment, nearly half of patients have permanent joint dysfunction. 
 
The main aim of this thesis was to investigate the inflammatory response of the host to living as well as 
antibiotics-killed S. aureus and to study the effect of biologics on the course of staphylococcal 
infections.  The role of host inflammatory response on post-infectious joint dysfunction using 
antibiotic-killed S. aureus was the subject of Paper I of this thesis. The main focus of Paper II and III 
were to study the effects of different biologics treatments on S. aureus induced septic arthritis and 
sepsis. 
 
We demonstrated that antibiotic-killed S. aureus is capable of inducing and maintaining destructive 
arthritis. By using different knockout mice, we showed that this type of arthritis was mediated through 
TLR-2, TNFR1 and RAGE receptors. Furthermore, we found that insoluble cell debris was a key 
initiator of this type of arthritis. Finally, anti-TNF therapy attenuated the arthritis caused by antibiotic-
killed S. aureus. 
 
All the biologic treatments tested (including anti-TNF therapy, CTLA4-Ig and IL-1 Ra) aggravated S. 
aureus infections but had different clinical manifestations. Both CTLA4-Ig and IL-1 Ra therapy 
significantly increased the susceptibility to S. aureus induced septic arthritis in mice. Anti-TNF therapy 
on the other hand resulted in more severe weight loss and impaired the bacterial clearance ability of the 
host. 
 
In conclusion, antibiotic-killed S. aureus induced chronic destructive arthritis and anti-TNF therapy 
attenuated this type of joint inflammation. In the living S. aureus induced septic arthritis, all tested 
biologics complicated the disease course.  Therefore, the potential dangers associated with biologics 
should be taken into account and patients with high risk of S. aureus bacteremia might be considered to 
refrain from them. 
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